Company intelligence / Profile preview

Tarsus Pharmaceuticals, Inc.

Irvine, California, United Statestarsusrx.com ↗

Ownership: Public · TARS
Employees: ~323
Development stage: Commercial

Overview

Tarsus has successfully launched XDEMVY (lotilaner ophthalmic solution, 0.25%), the first and only FDA-approved treatment for Demodex blepharitis. In Q1 2025, they generated $78.3 million in net product sales, an increase of 217% year over year and 18% over Q4 2024[8].

Therapeutic areas: OphthalmologyInfectious Diseases
Modalities: Small molecules (lotilaner)
Industry: Biotech

Drug pipeline

6 assets

lotilaner

Approved

5 more assets in the full pipeline.

Request access →

Partnerships

LianBio (Greater China)Grand Pharmaceutical Group (China)

Financials

Market cap: $3.5B
Total revenue: $173.9M
Enterprise value: $3.1B

Beyond the preview

Go deeper on Tarsus Pharmaceuticals, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tarsus Pharmaceuticals, Inc..

Explore the full profile